|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNFA and DRB I alleles were not significantly associated with PsA.
|
12022360 |
2002 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life.
|
29411182 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 54 patients with RA, 10 with PsA and 22 with AS were genotyped by polymerase chain reaction for the -308 TNFalpha promoter polymorphism.
|
16720636 |
2007 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNF gene polymorphisms may be useful prognostic markers in PsA, and these results support the rationale for using anti-TNF treatment in patients with severe, progressive PsA.
|
12746914 |
2003 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
373 controls and 137 SpA (82 with Psoriatic Arthritis-PsA and 55 with Ankylosing Spondylitis- AS; 98/137 under TNFα inhibitor therapy) from the Veneto Region (Italy) were studied.
|
29579081 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p < 0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p < 0.001) than patients who were classified as axPsA.
|
29948352 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of single-nucleotide polymorphisms (SNPs) at positions -238, -308, and +489 of the TNF-α gene in the genetic susceptibility to PsA, in the severity of the disease, and, finally, in the response to TNF-α inhibitors (adalimumab, etanercept, or infliximab).
|
24594669 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population.
|
21954344 |
2011 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association to PsA was observed in the presence of polymorphisms: TNF-238 G > A (rs361525), -308 G > A (rs1800629), and -857 C > T (rs1799724); IL12B C > G (rs6887695) and A > C (rs3212227); IL23A A > G (rs2066808) and IL23R G > A (rs11209026).
|
30584776 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that allelic variations at the TNFalpha locus influence susceptibility to PsA.
|
11830425 |
2002 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris.
|
15654990 |
2005 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the frequency of TNFA allele -238A was not increased in the total PsA group or in patients with a younger age of onset of psoriasis, TNFA allele -238A was absent in the spondyloarthritis group and increased in frequency in patients with peripheral polyarthritis.
|
12011375 |
2002 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study shows a strong association of the tumor necrosis factor-alpha promoter polymorphism at position -238 with psoriasis and psoriatic arthritis.
|
9326391 |
1997 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TNF-alpha gene has single nucleotide polymorphisms (SNPs) at positions -308 (-308G>A) and -238 (-238G>A) in the promoter region, and the -238G>A SNP has been reported to be associated with psoriasis vulgaris (PV) and psoriatic arthritis in Caucasians.
|
14657629 |
2003 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of this collaborative study indicate that TNF*-857T is a susceptibility allele for PsA independent of the PSORS1 allele.
|
22127698 |
2011 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine whether polymorphisms in Fcgamma receptor type IIIA (FcgammaRIIIA) correlate with clinical efficacy in patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) being treated with tumor necrosis factor alpha (TNFalpha) inhibitors.
|
16142749 |
2005 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All the variables concerning PsA activity showed a statistically significant improvement when comparing T6 and T12 with T0.
|
28589323 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with PsA with active enthesitis were randomized 1:1 to receive either ustekinumab (UST; arm 1) or tumor necrosis factor inhibitors (TNFi; arm 2).
|
30037432 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, the variant genotypes and alleles of TNFα -238A/G and -857T/C had an increased risk of PsV&PsA (OR = 2.493, 2.228, 1.536, 1.486, 95% CI, 1.777-3.498, 1.628-3.049, 1.336-1.767, 1.309-1.685).
|
23717605 |
2013 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Complex role of TNF variants in psoriatic arthritis and treatment response to anti-TNF therapy: evidence and concepts.
|
25219647 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Susceptibility to psoriatic arthritis was associated with the TNF -238 G/A genotype (P = 0.02).
|
26470763 |
2016 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After correction for multiple testing with a false discovery rate of 5%, two SNPs remained significant: TNF (rs361525) was associated with PsO, PsC10, and PsA; and IL12B (rs6887695) was associated with PsO.
|
29389950 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Etanercept is a soluble tumor necrosis factor (TNF) receptor originally approved for treatment of moderate-to-severe rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic arthritis.
|
21996051 |
2011 |